Evidence map›Paper›PMID 42582055›Full record

ArticleFrontiers in molecular biosciences2026

Development and evaluation of explainable machine learning models for predicting prognosis in patients with primary biliary cholangitis.

Yifeng Dou, Jiantao Liu

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yifeng DouNetwork Information Center, Tianjin Medical University Baodi Hospital, Tianjin, China.
Jiantao LiuDepartment of Traditional Chinese Medicine, Tianjin Medical University Baodi Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to develop, validate and evaluate interpretable machine learning models using clinical and laboratory data for prognosis prediction in patients with primary biliary cholangitis (PBC). Methods: This study included 7905 patients treated for PBC. The cohort data were randomly divided into training and testing sets, with external validation using an additional 2372 patients. Six machine learning models are compared in this research (logistic regression (LR), random forest (RF),Extreme Random Trees (ET), Extreme Gradient Boosting (XGBoost), Lightweight Gradient Boosting Machine (LightGBM), and Multi-Layer Perceptron (MLP)). Feature importance and model interpretation were analyzed using the SHapley Additive exPlanations (SHAP) method. Results: Ensemble tree models demonstrated significantly superior performance compared to traditional linear models and shallow neural networks in predicting PBC patient prognosis. Among these, the Extreme Random Tree model exhibited optimal predictive efficacy on both the training set (AUC = 0.9898) and external validation set (AUC = 0.9681), while the Random Forest model showed comparable performance with greater stability. At the patient level, SHAP's force maps and decision trees provided clinically meaningful explanations for the et algorithm. The bilirubin_albumin_ratio emerged as the core feature for predicting PBC prognosis, with bilirubin, n_days, and prothrombin serving as key influencing factors. The influence patterns of these features align closely with clinical and pathological mechanisms. Conclusion: The ET model constructed in this study enables precise prognosis prediction for PBC patients. After SHAP analysis, it demonstrates good interpretability. The key prognostic features identified by the model provide quantitative evidence for clinically assessing disease severity in PBC patients and offer data support for developing individualized clinical intervention plans.

Indexed as

extreme random treesinterpretabilitymachine learningpredictionprimary biliary cholangitis

Identifiers

PMID42582055
PMCPMC13457136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.